Healthcare analysts project a 50% increase in annual sales for weight-loss drugs, estimating a market value of $150 billion by the early 2030s. Key players include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, which have captured widespread interest despite limited insurance coverage. Analysts note these drugs could soon be covered by insurers due to their potential in preventing costly health emergencies. Despite 2023 shortages, increased production is underway. Shares in Lilly and Novo have surged, reflecting their growing market dominance. Discover the future of obesity treatment with 80 experimental drugs in the pipeline.
first published: May 29, 2024 11:57 am
A collection of the most-viewed Moneycontrol videos.
Live: Can Bihar poll outcome trigger Nifty to reclaim 26,000-mark? | Opening Bell
Live: Nifty holds above 25,900 but off nearly 100 pts from day's high | Closing Bell
Live: Will Nifty reclaim 26,000-mark amid record low inflation in Oct? | Opening Bell
Live: Nifty extends gain to third day, above 25,850 amid broad-based buying | Closing Bell
